Overview

Docetaxel in Locally Advanced Gastric Adenocarcinoma

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
Study objectives: To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sanofi
Treatments:
Cisplatin
Docetaxel
Fluorouracil